Matches in SemOpenAlex for { <https://semopenalex.org/work/W3098161529> ?p ?o ?g. }
- W3098161529 endingPage "e037700" @default.
- W3098161529 startingPage "e037700" @default.
- W3098161529 abstract "Introduction Erythema nodosum leprosum (ENL) is an immunological complication of leprosy. ENL results in morbidity and disability and if it is not treated can lead to death. The current treatment consists of thalidomide or high doses of oral corticosteroids for prolonged periods. Thalidomide is not available in many leprosy endemic countries. The use of corticosteroids is associated with morbidity and mortality. Identifying treatment regimens that reduce the use of corticosteroids in ENL is essential. Methotrexate (MTX) is used to treat many inflammatory diseases and has been used successfully to treat patients with ENL not controlled by other drugs, including prednisolone and thalidomide. We present the protocol of the ‘MTX and prednisolone study in ENL’ (MaPs in ENL) a randomised controlled trial (RCT) designed to test the efficacy of MTX in the management of ENL. Methods and analysis MaPs in ENL is an international multicentre RCT, which will be conducted in leprosy referral centres in Bangladesh, Brazil, Ethiopia, India, Indonesia and Nepal. Patients diagnosed with ENL who consent to participate will be randomly allocated to receive 48 weeks of weekly oral MTX plus 20 weeks of prednisolone or 48 weeks of placebo plus 20 weeks of prednisolone. Participants will be stratified by type of ENL into those with acute ENL and those with chronic and recurrent ENL. The primary objective is to determine whether MTX reduces the requirement for additional prednisolone. Patients’ reported outcome measures will be used to assess the efficacy of MTX. Participants will be closely monitored for adverse events. Ethics and dissemination Results will be submitted for publication in peer-reviewed journals. Ethical approval was obtained from the Observational/Interventions Research Ethics Committee of the London School of Hygiene & Tropical Medicine (15762); The Leprosy Mission International Bangladesh Institutional Research Board (in process); AHRI-ALERT Ethical Review Committee, Ethiopia; Ethics Committee of the Managing Committee of the Bombay Leprosy Project; and The Leprosy Mission Trust India Ethics Committee; the Nepal Health and Research Council and Health Research Ethics Committee Dr. Soetomo, Indonesia. This study is registered at www.clinicaltrials.gov . This is the first RCT of MTX for ENL and will contribute to the evidence for the management of ENL. Trial registration number NCT 03775460." @default.
- W3098161529 created "2020-11-23" @default.
- W3098161529 creator A5002991261 @default.
- W3098161529 creator A5005556001 @default.
- W3098161529 creator A5007115319 @default.
- W3098161529 creator A5011103287 @default.
- W3098161529 creator A5014235263 @default.
- W3098161529 creator A5016138432 @default.
- W3098161529 creator A5021268755 @default.
- W3098161529 creator A5021368215 @default.
- W3098161529 creator A5021996838 @default.
- W3098161529 creator A5033310372 @default.
- W3098161529 creator A5034966044 @default.
- W3098161529 creator A5038879920 @default.
- W3098161529 creator A5046548561 @default.
- W3098161529 creator A5055522113 @default.
- W3098161529 creator A5059058852 @default.
- W3098161529 creator A5072294669 @default.
- W3098161529 creator A5074173061 @default.
- W3098161529 creator A5074340566 @default.
- W3098161529 creator A5089387367 @default.
- W3098161529 creator A5091780630 @default.
- W3098161529 date "2020-11-01" @default.
- W3098161529 modified "2023-10-16" @default.
- W3098161529 title "Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial" @default.
- W3098161529 cites W1545080866 @default.
- W3098161529 cites W1592233687 @default.
- W3098161529 cites W1992401971 @default.
- W3098161529 cites W2008103734 @default.
- W3098161529 cites W2012172023 @default.
- W3098161529 cites W2018702353 @default.
- W3098161529 cites W2023219615 @default.
- W3098161529 cites W2034528800 @default.
- W3098161529 cites W2043315178 @default.
- W3098161529 cites W2049416062 @default.
- W3098161529 cites W2089738363 @default.
- W3098161529 cites W2093274439 @default.
- W3098161529 cites W2120825367 @default.
- W3098161529 cites W2129152730 @default.
- W3098161529 cites W2138976024 @default.
- W3098161529 cites W2140020442 @default.
- W3098161529 cites W2147149796 @default.
- W3098161529 cites W2153972688 @default.
- W3098161529 cites W2167909515 @default.
- W3098161529 cites W2173911615 @default.
- W3098161529 cites W2247856738 @default.
- W3098161529 cites W22738833 @default.
- W3098161529 cites W2278988336 @default.
- W3098161529 cites W2290751008 @default.
- W3098161529 cites W2296738739 @default.
- W3098161529 cites W2505069765 @default.
- W3098161529 cites W2594722112 @default.
- W3098161529 cites W2614016962 @default.
- W3098161529 cites W2725641531 @default.
- W3098161529 cites W2979313800 @default.
- W3098161529 cites W3081802981 @default.
- W3098161529 cites W3097184152 @default.
- W3098161529 doi "https://doi.org/10.1136/bmjopen-2020-037700" @default.
- W3098161529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7674097" @default.
- W3098161529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33203627" @default.
- W3098161529 hasPublicationYear "2020" @default.
- W3098161529 type Work @default.
- W3098161529 sameAs 3098161529 @default.
- W3098161529 citedByCount "6" @default.
- W3098161529 countsByYear W30981615292021 @default.
- W3098161529 countsByYear W30981615292022 @default.
- W3098161529 countsByYear W30981615292023 @default.
- W3098161529 crossrefType "journal-article" @default.
- W3098161529 hasAuthorship W3098161529A5002991261 @default.
- W3098161529 hasAuthorship W3098161529A5005556001 @default.
- W3098161529 hasAuthorship W3098161529A5007115319 @default.
- W3098161529 hasAuthorship W3098161529A5011103287 @default.
- W3098161529 hasAuthorship W3098161529A5014235263 @default.
- W3098161529 hasAuthorship W3098161529A5016138432 @default.
- W3098161529 hasAuthorship W3098161529A5021268755 @default.
- W3098161529 hasAuthorship W3098161529A5021368215 @default.
- W3098161529 hasAuthorship W3098161529A5021996838 @default.
- W3098161529 hasAuthorship W3098161529A5033310372 @default.
- W3098161529 hasAuthorship W3098161529A5034966044 @default.
- W3098161529 hasAuthorship W3098161529A5038879920 @default.
- W3098161529 hasAuthorship W3098161529A5046548561 @default.
- W3098161529 hasAuthorship W3098161529A5055522113 @default.
- W3098161529 hasAuthorship W3098161529A5059058852 @default.
- W3098161529 hasAuthorship W3098161529A5072294669 @default.
- W3098161529 hasAuthorship W3098161529A5074173061 @default.
- W3098161529 hasAuthorship W3098161529A5074340566 @default.
- W3098161529 hasAuthorship W3098161529A5089387367 @default.
- W3098161529 hasAuthorship W3098161529A5091780630 @default.
- W3098161529 hasBestOaLocation W30981615291 @default.
- W3098161529 hasConcept C126322002 @default.
- W3098161529 hasConcept C141071460 @default.
- W3098161529 hasConcept C142724271 @default.
- W3098161529 hasConcept C16005928 @default.
- W3098161529 hasConcept C168563851 @default.
- W3098161529 hasConcept C197934379 @default.
- W3098161529 hasConcept C204787440 @default.
- W3098161529 hasConcept C27081682 @default.
- W3098161529 hasConcept C2776364478 @default.